CD274 and non-small cell lung carcinoma: More interestingly, subgroups analyses confirmed across all potential confounding factors (such as line of treatment, type of NGS panel with various among of genome covered, level of PD-L1 expression, and ICI regimen) that bTMB was able to independently predict clinical issues for NSCLC patients treated by ICI.